Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | SMO | Q99835 | 2/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933666 | 0.92 | TGFBR1 (0.45) | TGFBR1PIM1SMOHSD17B1HSD17B2 | |
| SCHEMBL19933741 | 0.89 | MAP4K4 (0.49) | CNR1MAP4K4HSD17B1HSD17B2CTRC | |
| SCHEMBL19933718 | 0.88 | TGFBR1 (0.51) | TGFBR1HSD17B1HSD17B2WNT3A | |
| SCHEMBL18015693 | 0.87 | NPC1 (0.46) | TGFBR1CNR1MAP4K4HSD17B1HSD17B2 | |
| SCHEMBL19933687 | 0.85 | TGFBR1 (0.48) | TGFBR1CNR1MAP4K4PIM1SMO | |
| SCHEMBL19933725 | 0.84 | ALDH1A1 (0.44) | TGFBR1PIM1SMOHSD17B1HSD17B2 | |
| SCHEMBL18573198 | 0.84 | LDHA (0.45) | MAP4K4HSD17B1HSD17B2CTRCALDH1A2 | |
| SCHEMBL21125931 | 0.82 | HSD17B1 (0.56) | HSD17B1HSD17B2 | |
| SCHEMBL18015574 | 0.82 | LDHA (0.52) | HSD17B1HSD17B2 | |
| SCHEMBL19933578 | 0.82 | LDHA (0.52) | HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507294-B1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2021-02-24 | — | — | EP | disclosed |
| US-10889604-B2 | Binuclear and trinuclear metal complexes composed of two inter-linked tripodal hexadentate ligands for use in electroluminescent devices | MERCK PATENT GMBH | 2021-01-12 | — | — | US | disclosed |
| US-20190202851-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2019-07-04 | — | — | US | disclosed |
| WO-2018041769-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202851-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | PARN, PUF60, PARG | TGFBR1 2350/4885CNR1 4303/4885MAP4K4 3458/4885 |
| US-10889604-B2 | Binuclear and trinuclear metal complexes composed of two inter-linked tripodal hexadentate ligands for use in electroluminescent devices | PARN, PUF60, PARG | TGFBR1 2350/4885CNR1 4303/4885MAP4K4 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.